Compare REGN & GD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | GD |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.9B | 86.9B |
| IPO Year | 1991 | N/A |
| Metric | REGN | GD |
|---|---|---|
| Price | $752.98 | $340.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 17 |
| Target Price | ★ $795.74 | $352.94 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 02-03-2026 | 01-28-2026 |
| Dividend Yield | 0.47% | ★ 1.78% |
| EPS Growth | 2.88 | ★ 17.69 |
| EPS | ★ 41.59 | 15.44 |
| Revenue | $14,247,800,000.00 | ★ $51,509,000,000.00 |
| Revenue This Year | $1.95 | $12.04 |
| Revenue Next Year | $5.47 | $4.55 |
| P/E Ratio | ★ $17.82 | $21.86 |
| Revenue Growth | 2.89 | ★ 11.86 |
| 52 Week Low | $476.49 | $239.20 |
| 52 Week High | $790.98 | $360.50 |
| Indicator | REGN | GD |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 51.22 |
| Support Level | $689.88 | $336.73 |
| Resistance Level | $753.61 | $344.94 |
| Average True Range (ATR) | 20.54 | 5.35 |
| MACD | -4.30 | 0.12 |
| Stochastic Oscillator | 61.83 | 67.26 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments are aerospace, marine, combat systems, and technologies. General Dynamics' aerospace segment manufactures Gulfstream business jets and operates a global aircraft servicing operation. Combat systems produces land-based combat vehicles such as the M1 Abrams tank and Stryker armored personnel carrier, as well as munitions. The marine segment builds and services nuclear-powered submarines, destroyers, and Navy support ships. The technologies segment contains two main units: an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computing, intelligence, surveillance, and reconnaissance capabilities to the military.